Entering text into the input field will update the search result below

Acasti says candidate for subarachnoid hemorrhage met main goals in pivotal PK study

Dec. 02, 2021 7:40 AM ETAcasti Pharma Inc. (ACST), ACST:CABy: Dulan Lokuwithana, SA News Editor
  • Acasti Pharma (NASDAQ:ACST) said that its pivotal pharmacokinetic (PK) bridging study for GTX-104 reached all primary endpoints based on an interim look at the data from the first 20 of 50 normal healthy subjects in the trial.
  • Being developed as

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.